Sofinnova Partners charging ahead in Italy

Related Deal lead

Related Strategy

Corriere Della Sera, the leading Italian daily, published an article Nov. 22 detailing how Sofinnova Partners is "charging ahead" in Italy, investing €46 million in the country over 2 years and picking up an increasing number of local investors for Sofinnova Partners' Italian projects, the Sofinnova Telethon Strategy and the BiovelocIta accelerator.

"All the work we have done in Italy since 2015 has borne fruit," Graziano Seghezzi, managing partner at Sofinnova Partners, is quoted as saying. "We closed more than half of the 15 investments announced. We tripled the number of Italian investors in our fund, now they are 17 between institutional investors and family offices.”

Seghezzi pointed out that Sofinnova’s Milan offices house the “largest team in Italy dedicated to biotechnology” and that the company assessed 500 investments in Italy over the past three years.

Read the original article, written by Alessandra Puato and published in the weekly insert L'Economia (In Italian).

Sofinnova Partners charging ahead in Italy

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. join forces, building the next era of best-and first-in-class ophthalmic medicines

AAVantgarde Bio announces FDA Orphan Drug Designation for AAVB-081 for the treatment of Usher Syndrome type 1B Retinitis Pigmentosa

AAVantgarde Founder and CSO is elected as President of the European Society of Gene and Cell Therapy (ESGCT)

AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic

AAVantgarde announces first patient dosed with AAVB-081 in FIH Phase 1/2 LUCE-1 study for retinitis pigmentosa related to USH1B